This resource is for educational purposes only. It does not constitute medical advice. We do not sell peptides or recommend products.

1. Overview

Leuphasyl (INCI name: Pentapeptide-18) is a synthetic pentapeptide with the sequence Tyr-D-Ala-Gly-Phe-Leu, developed by Lipotec (now Lubrizol) as a cosmeceutical anti-wrinkle ingredient [2][5]. Its design is based on the natural enkephalin opioid pentapeptides -- leucine-enkephalin (Tyr-Gly-Gly-Phe-Leu) and methionine-enkephalin (Tyr-Gly-Gly-Phe-Met) -- first identified by Hughes et al. in 1975 as endogenous ligands of opioid receptors in the brain [1].

The key structural difference between Leuphasyl and natural leucine-enkephalin is the substitution of a D-alanine residue at position 2 in place of the glycine found in the natural peptide. This D-amino acid substitution is a well-established peptide engineering strategy that increases resistance to enzymatic degradation while maintaining receptor binding affinity, as endogenous peptidases typically recognize only L-amino acid substrates [2][4].

Leuphasyl is classified as a neurotransmitter-inhibiting peptide, specifically targeting the pre-synaptic side of the neuromuscular junction [2][3][4]. In the natural nervous system, enkephalins modulate neurotransmitter release by binding to opioid receptors (primarily delta-opioid receptors) on nerve terminals, where they activate G-protein-mediated inhibition of voltage-gated calcium channels. Reduced calcium influx decreases synaptic vesicle fusion and neurotransmitter (acetylcholine) release [8]. Leuphasyl mimics this pre-synaptic inhibitory mechanism in the context of facial motor neurons, theoretically reducing the frequency and intensity of muscle contractions that produce expression wrinkles.

This pre-synaptic mechanism distinguishes Leuphasyl from Argireline (Acetyl Hexapeptide-8) and SNAP-8 (Acetyl Octapeptide-3), which act post-synaptically by interfering with SNARE complex assembly to prevent acetylcholine vesicle fusion [7]. The two approaches target different steps in the neuromuscular transmission cascade, providing the rationale for their combination in cosmetic formulations for enhanced wrinkle reduction [2][3][6].

Sequence: Tyr-D-Ala-Gly-Phe-Leu (YAGFL with D-alanine at position 2)
Molecular Weight: ~569.65 g/mol
Number of Amino Acids: 5 (pentapeptide)
Mechanism: Pre-synaptic neuromuscular modulator via enkephalin pathway
INCI Name: Pentapeptide-18
Trade Name: Leuphasyl (Lipotec / Lubrizol)
Routes Studied: Topical (cream/serum)
FDA Status: Not regulated as drug; marketed as cosmetic ingredient
WADA Status: Not specifically listed

2. Mechanism of Action

Enkephalin-Mimetic Pathway

The proposed mechanism of Leuphasyl follows the natural enkephalin inhibitory pathway [1][8]:

Receptor binding: Leuphasyl binds opioid receptors (primarily delta-opioid receptors) on the pre-synaptic motor nerve terminal
G-protein activation: Receptor activation couples to inhibitory G-proteins (Gi/Go)
Calcium channel inhibition: Gi/Go signaling reduces voltage-gated calcium channel opening probability
Reduced calcium influx: Decreased pre-synaptic calcium entry during action potentials
Decreased vesicle fusion: Lower calcium levels reduce the probability of synaptic vesicle exocytosis
Reduced acetylcholine release: Less neurotransmitter reaches the post-synaptic muscle membrane
Attenuated muscle contraction: Reduced endplate potential amplitude decreases the force and frequency of muscle contraction
Smoothed expression lines: Diminished repetitive muscle contraction allows skin to relax, reducing wrinkle depth

Pre-Synaptic vs. Post-Synaptic Approaches

The neuromuscular junction can be targeted at two distinct points [2][3][6]:

Pre-synaptic (Leuphasyl): Reduces the amount of acetylcholine released from the nerve terminal. This is a modulation of signal transmission -- the nerve still fires, but less neurotransmitter is released per action potential.

Post-synaptic (Argireline, SNAP-8): Interferes with SNARE complex assembly within the nerve terminal, preventing the molecular machinery required for vesicle fusion and neurotransmitter release. This blocks a later step in the exocytosis pathway [7].

These two mechanisms act at different molecular targets and are therefore predicted to be additive or synergistic when combined. Manufacturer data reports that the combination of 5% Leuphasyl with 10% Argireline produces greater wrinkle reduction than either peptide alone [2][5].

The Penetration Challenge

As with all neuromuscular-modulating cosmeceutical peptides, a fundamental question remains about whether topically applied Leuphasyl can reach the neuromuscular junction in sufficient concentrations to produce its proposed mechanism of action [10]. The neuromuscular junction lies at the interface of motor nerve terminals and muscle fibers beneath the dermis, separated from the skin surface by the stratum corneum, epidermis, and dermis. Studies with the related peptide Argireline have shown that only 0.22% of applied peptide reaches the stratum corneum and none is detected in the dermis [7]. Whether Leuphasyl achieves sufficient local concentrations at the neuromuscular junction to activate opioid receptors remains unproven in published independent research.

3. Pharmacokinetics

Topical Absorption and Distribution

Leuphasyl presents a mixed pharmacokinetic profile for topical delivery [2][4][10]:

Molecular weight. At approximately 569.65 Da, Leuphasyl slightly exceeds the empirical 500 Da cutoff for efficient transdermal delivery but is substantially smaller than SNAP-8 (1,075 Da) and moderately smaller than Argireline (889 Da). This places it in an intermediate position for stratum corneum penetration.

Lipophilicity. The sequence Tyr-D-Ala-Gly-Phe-Leu contains two aromatic residues (tyrosine and phenylalanine) and a branched aliphatic residue (leucine), conferring moderate lipophilicity compared to the more hydrophilic SNAP-8 and Argireline. The estimated LogP is more favorable for stratum corneum partitioning than highly hydrophilic peptides, though published LogP values are not available.

D-alanine metabolic stability. The D-alanine substitution at position 2 significantly enhances resistance to aminopeptidase degradation compared to the all-L-amino acid leucine-enkephalin. Skin-resident aminopeptidases, which cleave N-terminal L-amino acids, have markedly reduced activity against D-amino acid substrates. This modification extends the dermal half-life of Leuphasyl relative to its natural enkephalin counterpart [2][4][8].

Enkephalin pathway kinetics. The opioid receptor signaling cascade (receptor binding, G-protein activation, calcium channel modulation) occurs on a timescale of seconds to minutes. If Leuphasyl reaches opioid receptors on motor nerve terminals, the pharmacological effect would be relatively rapid compared to mechanisms requiring gene transcription (e.g., matrikine signaling). However, the kinetics of skin penetration to the neuromuscular junction depth (hours to days) would dominate the overall onset time [8].

Target depth problem. Like all neuromuscular cosmeceutical peptides, Leuphasyl must traverse the full skin thickness to reach opioid receptors on motor nerve terminals at the neuromuscular junction. Based on Argireline penetration data (0.22% SC penetration, no dermal detection), the estimated concentration of intact Leuphasyl at neuromuscular junction depth is in the sub-nanomolar range -- likely below the EC50 for delta-opioid receptor activation [7][10].

Systemic absorption. Systemic absorption is considered negligible at cosmetic concentrations. Even if small amounts reached the systemic circulation, the D-alanine substitution would not prevent rapid renal clearance and hepatic metabolism, limiting any potential for systemic opioid effects.

Comparison with Dalargin

Leuphasyl is a shorter derivative of dalargin (Tyr-D-Ala-Gly-Phe-Leu-Arg), a hexapeptide studied as an anti-ulcer agent in the former Soviet Union. Dalargin has documented analgesic and anti-stress properties when administered systemically, but at much higher doses than would be achievable through topical cosmetic application. The pharmacokinetic profile of Leuphasyl differs from dalargin primarily in the absence of the C-terminal arginine, which may affect receptor subtype selectivity and metabolic stability [2][8].

4. Dose-Response Relationship

Clinical Concentration-Response

Manufacturer-sponsored data from Lipotec provides the primary dose-response information [2][5]:

| Protocol | Concentration | Duration | Wrinkle Reduction | |---|---|---|---| | Leuphasyl alone | 5% trade solution, BID | 28 days | Up to 47% | | Leuphasyl + Argireline | 5% Leuphasyl + 10% Argireline, BID | 28 days | Greater than either alone | | Low-dose maintenance | 3% trade solution, BID | Ongoing | Not precisely reported |

Synergy with Argireline/SNAP-8

The most pharmacologically significant dose-response finding is the synergistic interaction between Leuphasyl and SNARE-inhibiting peptides [2][5]:

Leuphasyl alone (5%): Up to 47% wrinkle reduction at 28 days
Argireline alone (10%): Up to 27% wrinkle reduction at 28 days
Combination (5% Leuphasyl + 10% Argireline): Reported to exceed either peptide alone

The proposed mechanism for this synergy is that Leuphasyl reduces calcium-dependent vesicle fusion probability (upstream) while Argireline/SNAP-8 reduces SNARE-mediated fusion efficiency (downstream), creating additive inhibition of acetylcholine release at two independent molecular steps [2][3].

Time Course

Based on manufacturer data and the proposed mechanism [2][5]:

Days 1-7: Minimal measurable change; peptide accumulation phase
Days 7-14: Initial wrinkle smoothing effects
Days 14-28: Progressive improvement; peak manufacturer-reported effects at day 28
Post-discontinuation: Effects expected to reverse within days to weeks as neuromuscular function normalizes

5. Comparative Effectiveness

Leuphasyl vs. Argireline/SNAP-8

| Parameter | Leuphasyl | Argireline | SNAP-8 | |---|---|---|---| | Mechanism | Pre-synaptic opioid receptor | Pre-synaptic SNARE inhibition | Pre-synaptic SNARE inhibition | | Target | Delta-opioid receptor | SNAP-25/syntaxin-1 interaction | SNAP-25/syntaxin-1 interaction | | Molecular weight | ~569.65 Da | ~889 Da | ~1,075 Da | | D-amino acid | Yes (position 2) | No | No | | 28-day wrinkle reduction | Up to 47% (5% solution) | Up to 27% (10% solution) | Up to 35% (10% solution) | | Independent clinical data | None published | Limited (2-3 studies) | None published | | Synergy with Argireline | Yes (different target) | N/A | Similar mechanism to Argireline | | Metabolic stability | Enhanced (D-Ala) | Moderate (N-acetyl cap) | Moderate (N-acetyl cap) |

Leuphasyl's key advantage is its unique mechanism of action, which provides genuine synergy with SNARE-inhibiting peptides rather than mere additive effects at the same target [2][3][6].

Leuphasyl vs. SYN-AKE

| Parameter | Leuphasyl | SYN-AKE | |---|---|---| | Mechanism | Pre-synaptic (opioid receptor) | Post-synaptic (nAChR blockade) | | Target | Motor nerve terminal | Muscle membrane | | Molecular weight | ~569.65 Da | ~439.5 Da | | Below 500 Da | No | Yes | | 28-day wrinkle reduction | Up to 47% | Up to 52% | | Combination rationale | Complement with SYN-AKE (dual pre+post) | Complement with Leuphasyl (dual pre+post) |

Leuphasyl and SYN-AKE target opposite sides of the neuromuscular junction, making them theoretically the most complementary peptide combination for neuromuscular anti-wrinkle effects [3][6].

Leuphasyl vs. Botulinum Toxin

| Parameter | Leuphasyl | Botulinum Toxin Type A | |---|---|---| | Mechanism | Competitive opioid receptor agonism | Irreversible SNARE cleavage | | Administration | Topical (non-invasive) | Intramuscular injection | | Onset | 2-4 weeks (topical) | 24-72 hours | | Peak effect | ~47% wrinkle reduction | 80-100% muscle paralysis | | Duration | Requires continuous use | 3-6 months per treatment | | Natural expression | Fully preserved | May be reduced | | Evidence quality | Preliminary (manufacturer only) | Strong (thousands of RCTs) |

As with all topical neuromuscular peptides, the comparison with injectable botulinum toxin fundamentally favors the injectable for efficacy, while Leuphasyl offers non-invasive convenience and preserved facial expression [3][5].

6. Clinical Evidence

Manufacturer-Sponsored Data

Lipotec (the developer of Leuphasyl) has reported proprietary clinical data showing wrinkle depth reduction of up to 47% after 28 days of twice-daily application of 5% Leuphasyl solution [5]. When combined with 10% Argireline, the reported efficacy was enhanced beyond either peptide alone, consistent with the proposed synergistic pre-synaptic + post-synaptic mechanism [2][5].

Independent Academic Validation

Independent peer-reviewed clinical trials specifically evaluating Leuphasyl as a single ingredient are limited. The peptide is more commonly encountered in combination formulations with Argireline, SNAP-8, or other anti-wrinkle peptides, making it difficult to attribute clinical effects specifically to Leuphasyl [9][10]. Recent reviews have noted this gap in independent validation while acknowledging the theoretical soundness of the enkephalin-mimetic approach [9][10].

Study	Year	Type	Subjects	Key Finding
Hughes et al. -- Identification of enkephalin sequences	1975	Biochemical characterization	Porcine brain extracts	Identified methionine-enkephalin (Tyr-Gly-Gly-Phe-Met) and leucine-enkephalin (Tyr-Gly-Gly-Phe-Leu) as the endogenous opioid peptides binding to opioid receptors.
Lupo MP and Cole AL -- Cosmeceutical peptides	2007	Review	N/A (literature review)	Reviewed the mechanism of Leuphasyl as a pre-synaptic neuromuscular modulator for cosmetic wrinkle reduction, noting its enkephalin-mimetic design and complementary mechanism to Argireline.
Gorouhi and Maibach -- Role of topical peptides in aged skin	2009	Review	N/A (literature review)	Classified Leuphasyl as a neurotransmitter inhibitor peptide acting at the pre-synaptic level to modulate acetylcholine release, and noted its synergistic combination with Argireline.
Schagen -- Topical peptide treatments with anti-aging results	2017	Review	N/A (literature review)	Described Leuphasyl's mechanism as mimicking the natural inhibition of neurotransmitter release by enkephalins at motor nerve terminals, reducing muscular contraction and expression lines.
Pai et al. -- Topical peptides as cosmeceuticals	2017	Review	N/A (literature review)	Categorized Leuphasyl among neurotransmitter inhibitor peptides and noted manufacturer claims of up to 47% wrinkle reduction after 28 days at 5% concentration.
Ferreira et al. -- Trending anti-aging peptides	2020	Review	N/A (literature review)	Identified Leuphasyl as a trending cosmeceutical peptide ingredient, noting its complementary pre-synaptic mechanism to post-synaptic SNARE inhibitors like Argireline and SNAP-8.
Blanes-Mira et al. -- Argireline discovery and SNARE complex inhibition	2002	In vitro and clinical	Chromaffin cells; 10 female volunteers	Established the SNARE-complex inhibition mechanism for neuromuscular cosmeceutical peptides, the post-synaptic counterpart to Leuphasyl's pre-synaptic mechanism.
Snyder and Pasternak -- Historical and clinical perspectives on opioid receptors	2012	Review	N/A (literature review)	Reviewed the opioid receptor system including the mechanism by which enkephalins modulate neurotransmitter release at pre-synaptic terminals via G-protein-mediated calcium channel inhibition.
Song et al. -- Peptides for prevention and treatment of skin senescence	2025	Review	N/A (literature review)	Reviewed the current evidence for neurotransmitter-inhibiting cosmeceutical peptides including Leuphasyl, noting the continued lack of independent clinical validation.
Deprez et al. -- Bioactive peptides in cosmetic formulations	2025	Review	N/A (literature review)	Reviewed current in vitro and ex vivo evidence for cosmeceutical peptides including neuromuscular modulators, noting that topical penetration to the neuromuscular junction remains unproven.
Spectroscopic characterization and molecular interaction analysis of Pentapeptide-18	2026	Computational and spectroscopic study	Pentapeptide-18 molecular characterization	Comprehensive analysis combining quantum chemistry, vibrational spectroscopy, molecular docking, and molecular dynamics simulations revealed biophysical properties of Pentapeptide-18 capable of influencing cellular aging processes at the molecular level, providing the first detailed structural characterization of the peptide.

7. Dosing in Research

Dosages below are from published research studies only. They are not recommendations for human use.

Study / Context	Route	Dose	Duration
Lipotec proprietary data (wrinkle reduction)	Topical (cream/serum)	5% Leuphasyl trade solution	Twice daily for 28 days
Combination with Argireline (manufacturer data)	Topical (cream/serum)	5% Leuphasyl + 10% Argireline	Twice daily for 28 days

8. Safety and Side Effects

Leuphasyl has been used in cosmetic products without reports of significant adverse effects in the published literature [2][3][5]. As a cosmetic ingredient, it has not undergone the rigorous clinical safety evaluation required for pharmaceutical approval.

Key safety considerations:

No systemic opioid effects: At the low concentrations used in topical cosmetics (parts per million of active peptide), systemic absorption is negligible, and no opioid-like systemic effects (analgesia, respiratory depression, dependence) would be expected
Local tolerance: No reports of significant irritation, sensitization, or adverse skin reactions in published literature
Reversibility: Effects are expected to be fully reversible upon discontinuation, as the peptide modulates neurotransmitter release rather than causing structural changes
D-amino acid content: The D-alanine residue at position 2 is metabolically resistant, which is desirable for topical stability but means the peptide is not a natural substrate for standard peptidases

Enhanced Safety Considerations

Opioid receptor specificity. Leuphasyl mimics leucine-enkephalin and primarily targets delta-opioid receptors. Opioid receptors are present not only on motor nerve terminals but also on skin keratinocytes, melanocytes, and immune cells, where they modulate proliferation, differentiation, and immune function [1][8]. At cosmetic concentrations, significant activation of cutaneous opioid receptors is unlikely, but theoretical effects on local skin immune function or wound healing cannot be entirely excluded.

No dependence or tolerance risk. Opioid receptor agonists can produce tolerance and dependence through receptor desensitization and internalization mechanisms. However, these effects require sustained, pharmacologically relevant receptor occupancy. The sub-pharmacological concentrations of Leuphasyl expected to reach opioid receptors from topical application are far below the threshold for tolerance or dependence development [8].

Interaction with opioid medications. Patients using systemic opioid medications (e.g., for pain management) are unlikely to experience any interaction with topically applied Leuphasyl, as dermal absorption is negligible. However, this combination has not been formally studied [8].

D-alanine metabolism. D-amino acids are not normally incorporated into human proteins and are metabolized differently from L-amino acids. D-alanine is a substrate for D-amino acid oxidase (DAO), which converts it to pyruvate and ammonia. At the trace quantities released from topical Leuphasyl, this metabolic pathway is of no toxicological concern [2].

Tyrosine-derived melanogenic effects. Leuphasyl contains a tyrosine residue, which is the precursor for melanin synthesis. There is no evidence that topically applied Leuphasyl contributes to melanogenesis, as the tyrosine would need to enter melanocytes and be processed by tyrosinase -- an event not expected at cosmetic peptide concentrations [1].

Photostability. The tyrosine residue absorbs UV light (absorption maximum ~275 nm) and can undergo photo-oxidation. This may reduce peptide activity upon sun exposure but does not generate known toxic photoproducts. Sunscreen use alongside Leuphasyl is recommended for both anti-aging benefit and peptide preservation [4].

No long-term safety studies have been published, and the peptide has not been evaluated for use during pregnancy or lactation.

9. Regulatory Status

Leuphasyl is classified as a cosmetic ingredient (INCI: Pentapeptide-18) rather than a pharmaceutical. It is not approved as a drug by any regulatory agency and has not undergone clinical trials for therapeutic registration. It is not specifically listed on the WADA prohibited list.

11. References

[1] Hughes J, Smith TW, Kosterlitz HW, et al. (1975). Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature. DOI PubMed
[2] Lupo MP, Cole AL (2007). Cosmeceutical peptides. Dermatologic Therapy. DOI PubMed
[3] Gorouhi F, Maibach HI (2009). Role of topical peptides in preventing or treating aged skin. International Journal of Cosmetic Science. DOI PubMed
[4] Schagen SK (2017). Topical peptide treatments with effective anti-aging results. Cosmetics. DOI
[5] Pai VV, Bhandari P, Shukla P (2017). Topical peptides as cosmeceuticals. Indian Journal of Dermatology, Venereology and Leprology. DOI PubMed
[6] Ferreira MS, Magalhaes MC, Sousa-Lobo JM, Almeida IF (2020). Trending anti-aging peptides. Cosmetics. DOI
[7] Blanes-Mira C, Clemente J, Jodas G, et al. (2002). A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. PubMed
[8] Snyder SH, Pasternak GW (2012). Historical review: opioid receptors. Trends Pharmacol Sci. PubMed
[9] Song J, Kim D, Lee S, et al. (2025). Peptides: emerging candidates for the prevention and treatment of skin senescence. Int J Mol Sci. DOI PubMed
[10] Deprez S, Bhatt TK, Bhatt NP, et al. (2025). Bioactive peptides in cosmetic formulations: review of current in vitro and ex vivo evidence. Peptides. DOI
[11] Vargas-Castillo A, et al. (2025). Current approaches in cosmeceuticals: peptides, biotics and marine biopolymers. Molecules.
[12] Various authors (2026). Pentapeptide-18 as an anti-aging candidate: spectroscopic characterization and molecular interaction analysis. Journal of Molecular Structure.

Leuphasyl (Pentapeptide-18)